 Kavita Nair
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 7 | 2023 | 455 | 2.100 |
Why?
| | Insurance, Pharmaceutical Services | 6 | 2020 | 22 | 1.510 |
Why?
| | Drugs, Generic | 3 | 2021 | 22 | 1.410 |
Why?
| | Managed Care Programs | 6 | 2014 | 135 | 1.400 |
Why?
| | Chronic Disease | 6 | 2020 | 1793 | 1.020 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2022 | 76 | 0.950 |
Why?
| | Prescription Drugs | 2 | 2021 | 109 | 0.940 |
Why?
| | Drug Costs | 2 | 2025 | 106 | 0.870 |
Why?
| | Health Resources | 2 | 2016 | 120 | 0.810 |
Why?
| | Choice Behavior | 2 | 2020 | 170 | 0.770 |
Why?
| | Cost Sharing | 3 | 2020 | 15 | 0.760 |
Why?
| | Insurance Benefits | 3 | 2010 | 11 | 0.740 |
Why?
| | Nervous System Diseases | 2 | 2023 | 266 | 0.730 |
Why?
| | Retinal Degeneration | 1 | 2021 | 38 | 0.690 |
Why?
| | Health Services | 2 | 2009 | 107 | 0.570 |
Why?
| | Health Expenditures | 5 | 2017 | 189 | 0.540 |
Why?
| | Medicare Part D | 2 | 2021 | 25 | 0.520 |
Why?
| | Insurance Coverage | 2 | 2011 | 230 | 0.470 |
Why?
| | Hospital Costs | 1 | 2016 | 117 | 0.460 |
Why?
| | Chlorthalidone | 1 | 2014 | 5 | 0.460 |
Why?
| | Hydrochlorothiazide | 1 | 2014 | 9 | 0.460 |
Why?
| | Hypertension | 2 | 2014 | 1295 | 0.460 |
Why?
| | Patient Admission | 1 | 2016 | 197 | 0.430 |
Why?
| | Insurance, Health | 3 | 2016 | 283 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1313 | 0.420 |
Why?
| | Tetrazoles | 1 | 2013 | 41 | 0.420 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 38 | 0.420 |
Why?
| | Immunologic Factors | 2 | 2015 | 236 | 0.410 |
Why?
| | Antihypertensive Agents | 2 | 2014 | 494 | 0.400 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 350 | 0.390 |
Why?
| | Fibric Acids | 1 | 2012 | 3 | 0.390 |
Why?
| | Medicare | 3 | 2025 | 773 | 0.390 |
Why?
| | Gout Suppressants | 1 | 2012 | 20 | 0.390 |
Why?
| | Arthritis, Gouty | 1 | 2012 | 15 | 0.390 |
Why?
| | Acute Coronary Syndrome | 1 | 2016 | 279 | 0.380 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2025 | 804 | 0.380 |
Why?
| | Imidazoles | 1 | 2013 | 238 | 0.380 |
Why?
| | Drug Labeling | 1 | 2012 | 39 | 0.380 |
Why?
| | Absenteeism | 1 | 2012 | 49 | 0.380 |
Why?
| | Off-Label Use | 1 | 2012 | 52 | 0.370 |
Why?
| | Health Care Costs | 2 | 2012 | 398 | 0.370 |
Why?
| | Inpatients | 1 | 2016 | 500 | 0.360 |
Why?
| | Hospital Mortality | 1 | 2016 | 911 | 0.360 |
Why?
| | United States | 15 | 2025 | 14841 | 0.350 |
Why?
| | Retrospective Studies | 15 | 2024 | 15657 | 0.330 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 110 | 0.330 |
Why?
| | Blood Pressure | 2 | 2014 | 1786 | 0.320 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 445 | 0.320 |
Why?
| | Health Benefit Plans, Employee | 1 | 2009 | 25 | 0.310 |
Why?
| | Middle Aged | 19 | 2024 | 33479 | 0.300 |
Why?
| | Dyslipidemias | 2 | 2012 | 176 | 0.300 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1430 | 0.300 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 565 | 0.290 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 460 | 0.290 |
Why?
| | Program Development | 1 | 2010 | 364 | 0.290 |
Why?
| | Humans | 36 | 2025 | 137585 | 0.280 |
Why?
| | Loratadine | 2 | 2005 | 4 | 0.280 |
Why?
| | Male | 24 | 2025 | 67762 | 0.280 |
Why?
| | Negotiating | 2 | 2025 | 32 | 0.270 |
Why?
| | Diabetes Mellitus | 3 | 2017 | 1040 | 0.260 |
Why?
| | Nonprescription Drugs | 2 | 2005 | 63 | 0.260 |
Why?
| | Female | 24 | 2025 | 73304 | 0.260 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 293 | 0.250 |
Why?
| | Adult | 17 | 2024 | 37929 | 0.250 |
Why?
| | Models, Economic | 2 | 2016 | 58 | 0.240 |
Why?
| | Drug Prescriptions | 3 | 2005 | 245 | 0.230 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 11 | 0.230 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 413 | 0.230 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 11 | 0.220 |
Why?
| | Aged | 15 | 2025 | 23961 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 52 | 0.220 |
Why?
| | Aquaporin 4 | 1 | 2024 | 94 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 100 | 0.220 |
Why?
| | Insurance Claim Review | 3 | 2017 | 64 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2057 | 0.210 |
Why?
| | Neurology | 2 | 2023 | 113 | 0.210 |
Why?
| | Natalizumab | 2 | 2015 | 40 | 0.210 |
Why?
| | Prescription Fees | 1 | 2003 | 4 | 0.210 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 307 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 190 | 0.200 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 132 | 0.200 |
Why?
| | Young Adult | 8 | 2024 | 13209 | 0.190 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 131 | 0.190 |
Why?
| | Cost-Benefit Analysis | 5 | 2025 | 591 | 0.190 |
Why?
| | Information Services | 1 | 2001 | 49 | 0.180 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 180 | 0.180 |
Why?
| | Myeloid Cells | 1 | 2022 | 148 | 0.180 |
Why?
| | Neurologists | 1 | 2021 | 21 | 0.180 |
Why?
| | Atrophy | 1 | 2021 | 184 | 0.170 |
Why?
| | Community Participation | 1 | 2001 | 131 | 0.170 |
Why?
| | Infliximab | 2 | 2012 | 111 | 0.170 |
Why?
| | Rituximab | 1 | 2021 | 176 | 0.160 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1167 | 0.160 |
Why?
| | Attitude to Health | 1 | 2003 | 439 | 0.160 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.160 |
Why?
| | Patient Satisfaction | 1 | 2003 | 660 | 0.150 |
Why?
| | Cohort Studies | 4 | 2013 | 5742 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2022 | 847 | 0.130 |
Why?
| | Adolescent | 7 | 2024 | 21513 | 0.130 |
Why?
| | Pharmaceutical Services | 2 | 2011 | 83 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 916 | 0.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1081 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7635 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.120 |
Why?
| | Drug Utilization Review | 3 | 2005 | 57 | 0.120 |
Why?
| | Systole | 1 | 2014 | 189 | 0.110 |
Why?
| | Ambulatory Care | 2 | 2023 | 546 | 0.110 |
Why?
| | Losartan | 1 | 2013 | 14 | 0.110 |
Why?
| | Valsartan | 1 | 2013 | 29 | 0.100 |
Why?
| | Formularies as Topic | 2 | 2003 | 6 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 54 | 0.100 |
Why?
| | Linear Models | 1 | 2016 | 849 | 0.100 |
Why?
| | Valine | 1 | 2013 | 82 | 0.100 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 63 | 0.100 |
Why?
| | Biomarkers | 1 | 2024 | 4149 | 0.100 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.100 |
Why?
| | Gemfibrozil | 1 | 2012 | 11 | 0.100 |
Why?
| | Population Surveillance | 1 | 2016 | 482 | 0.100 |
Why?
| | Simvastatin | 1 | 2012 | 61 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2526 | 0.090 |
Why?
| | Hypolipidemic Agents | 1 | 2012 | 91 | 0.090 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 213 | 0.090 |
Why?
| | Mitoxantrone | 1 | 2011 | 14 | 0.090 |
Why?
| | Glatiramer Acetate | 1 | 2011 | 18 | 0.090 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 392 | 0.090 |
Why?
| | Prevalence | 3 | 2024 | 2734 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.090 |
Why?
| | Financing, Personal | 1 | 2011 | 26 | 0.090 |
Why?
| | Colorado | 3 | 2024 | 4565 | 0.090 |
Why?
| | Interferon-beta | 1 | 2011 | 92 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2010 | 75 | 0.080 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 97 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 617 | 0.080 |
Why?
| | Likelihood Functions | 1 | 2010 | 144 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1215 | 0.080 |
Why?
| | Spine | 1 | 2011 | 173 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2828 | 0.080 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 4 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 2 | 2024 | 113 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1316 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2014 | 10811 | 0.080 |
Why?
| | Patient Discharge | 1 | 2016 | 897 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 600 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 216 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1066 | 0.080 |
Why?
| | Transportation | 1 | 2009 | 53 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 52 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 1024 | 0.070 |
Why?
| | Pain Management | 1 | 2011 | 352 | 0.070 |
Why?
| | North America | 1 | 2009 | 313 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 629 | 0.070 |
Why?
| | Incidence | 2 | 2024 | 2804 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1266 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5778 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1242 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1139 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2014 | 1069 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1509 | 0.070 |
Why?
| | Program Evaluation | 1 | 2010 | 898 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 806 | 0.060 |
Why?
| | Peptides | 1 | 2011 | 985 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 2074 | 0.060 |
Why?
| | Anti-Allergic Agents | 1 | 2005 | 46 | 0.060 |
Why?
| | Time Factors | 1 | 2016 | 6828 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 140 | 0.060 |
Why?
| | Benchmarking | 1 | 2005 | 186 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2025 | 152 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5131 | 0.050 |
Why?
| | Histamine H2 Antagonists | 1 | 2004 | 30 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 365 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2844 | 0.050 |
Why?
| | Neuroglia | 1 | 2024 | 173 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2003 | 120 | 0.050 |
Why?
| | Patient Compliance | 2 | 2003 | 581 | 0.050 |
Why?
| | Pamphlets | 1 | 2001 | 23 | 0.050 |
Why?
| | Decision Making | 2 | 2015 | 900 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 740 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2023 | 565 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1291 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3457 | 0.040 |
Why?
| | Students, Pharmacy | 1 | 2001 | 97 | 0.040 |
Why?
| | Hospitalization | 1 | 2009 | 2199 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3566 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5472 | 0.030 |
Why?
| | Child | 3 | 2024 | 21935 | 0.030 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1060 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3715 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3556 | 0.030 |
Why?
| | Neurons | 1 | 2024 | 1590 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2035 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 746 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1289 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2014 | 227 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2015 | 421 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2071 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1357 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3295 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1477 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1622 | 0.020 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.010 |
Why?
| | California | 1 | 2005 | 431 | 0.010 |
Why?
| | Coronary Disease | 1 | 2003 | 385 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 11074 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 10388 | 0.000 |
Why?
|
|
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|